Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case

Surgery Today

Volumn 44, Issue 11, 2014, Pages 2195-2200

  Hibi, Yatsuka ^a   Ohye, Tamae ^b   Ogawa, Kimio ^a   Shimizu, Yoshimi ^a   Shibata, Masahiro ^a   Kagawa, Chikara ^a   Mizuno, Yutaka ^a   Uchino, Shinya ^c,e   Kosugi, Shinji ^d,e   Kurahashi, Hiroki ^b   Iwase, Katsumi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c Noguchi Thyroid Clinic and Hospital Foundation   (Japan)

^d KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^e MEN Consortium of Japan   (Japan)

Author keywords

MEN2A; Pheochromocytoma; RET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CALCITONIN; CALCIUM; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; PHOSPHORUS; PROTEIN RET; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN;

ADRENALECTOMY; ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CASE REPORT; CATECHOLAMINE URINE LEVEL; CELL HYPERPLASIA; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; MIDDLE AGED; ONCOGENE RET; PARATHYROID HORMONE BLOOD LEVEL; PHEOCHROMOCYTOMA; PHOSPHATE BLOOD LEVEL; PROVOCATION TEST; SIPPLE SYNDROME; THYROIDECTOMY; TUMOR VOLUME; ADRENAL GLAND NEOPLASMS; CHEMISTRY; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; GENETICS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PATHOLOGY; PEDIGREE; PROCEDURES; PROTEIN TERTIARY STRUCTURE; THYROID FUNCTION TEST; THYROID NEOPLASMS;

ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; CALCITONIN; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PEDIGREE; PHEOCHROMOCYTOMA; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; THYROID FUNCTION TESTS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84919384491     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0826-8     Document Type: Article

References (23)

1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.
2. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.
3. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267:381–3.
4. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.
5. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, et al. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:4176–8.
6. Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF. A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes. 1999;13:77–9.
7. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005;90:3999–4003.
8. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, et al. Pheochromocytoma and medullary thyroid carcinoma: a new genotype–phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004;89:4142–5.
9. Machens A, Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf). 2008;69:81–7.
10. Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, et al. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. J Clin Endocrinol Metab. 2010;95:E92–7.
11. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92:4725–9.
12. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype–phenotype relationship. Arch Surg. 2003;138:409–16 (discussion 416).
13. Asari R, Scheuba C, Kaczirek K, Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg. 2006;141:1199–205 (discussion 1205).
14. Paszko Z, Sromek M, Czetwertynska M, Skasko E, Czapczak D, Wisniewska A, et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred’s from Central Poland. Cancer Invest. 2007;25:742–9.
15. Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF. Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma. Rev Med Chil. 2001;129:713–8 (Spanish).
16. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol. 2006;155:229–36.
17. Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, MEN Consortium of Japan, et al. High penetrance of pheochromocytoma in multiple endocrineneoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol. 2013;168:683–7.
18. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612.
19. Plaza-Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, et al. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res. 2005;65:1729–37.
20. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene. 1999;18:3919–22.
21. Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, et al. A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Mol Endocrinol. 2006;20:1633–43.
22. Machens A, Dralle H. Genotype–phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007;31:957–68.
23. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D’etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab. 1998;83:487–91.